Media

Press Kit

Malin Media Pack

> Coming Soon

Reports & Presentations

2021 Interim Report

> download > go to Reports & Presentations page

Latest Press Releases

RNS Announcements

Investee Companies

Tue, 31 Aug 2021

Share Buyback

Thu, 26 Aug 2021

Interim Results 2021

Thu, 12 Aug 2021

Notice of 2021 Interim Results

Thu, 22 Jul 2021

Share Buyback

Thu, 22 Jul 2021

Result of AGM

News Archive>

22 Sep 2021

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

20 Sep 2021

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

13 Sep 2021

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

10 Sep 2021

Immunocore to present at upcoming investor conferences

08 Sep 2021

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

Media Contacts

Malin Media Contact

Tel: +353 (0)1 901 5717

mediarelations@malinplc.com
Ireland - Financial Media Contact

Powerscourt

Tel: +353 (0)1 536 0682

malin@powerscourt-group.com